Skip to Main content Skip to Navigation
Journal articles

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Emilie Reboursiere 1 Fabien Le Bras 2 Charles Herbaux 3, 4 Emmanuel Gyan 5, 6 Aline Clavert 7 Franck Morschhauser 8 Sandra Malak 9 David Sibon 10, 11 Florence Broussais 12 Thorsten Braun 13 Luc-Matthieu Fornecker 14 Reda Garidi 15 Sabine Tricot 16 Roch Houot 17, 18 Bertrand Joly 19 Wajed Abarah 20 Bachra Choufi 21 Anne-Dominique Pham 22, 23, 24 Anne-Claire Gac 25 Christophe Fruchart 1 Emilie Marin 1 Violaine Safar 26 Anne Parcelier 27 Hervé Maisonneuve 28 Emmanuel Bachy 29 Guillaume Cartron 30 Arnaud Jaccard 31, 32 Olivier Tournilhac 33, 34 Cédric Rossi 35 Luciane Schirmer 36 Jean-Alain Martignoles 37 Philippe Gaulard 38 Hervé Tilly 39 Gandhi Damaj 40, 41
Abstract : Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients.Between November 2009 and March 2015, 138 PTCL patients were treated with bendamustine in 27 centers. Population median age was 64 (28-89) years with male/female ratio of 1.4. There were mainly angio-immunoblastic (AITL = 71), PTCL-not otherwise specified (PTCL-NOS = 40) and anaplastic large cell lymphoma (ALCL = 8). The majority of patients (96%) had disseminated disease and extranodal localizations (77%). Median number of chemotherapy lines prior to bendamustine was 2 (1-8). Median duration of response (DoR) after the last chemotherapy prior to bendamustine was 4.3 months (1-70) and 50% of patients had refractory disease.Median number of administered bendamustine cycles was 2 (1-8) and 72 patients (52%) received less than 3 mostly because of disease progression. Median dose was 90 (50-150) mg/m(2). Overall response rate (ORR) was 32.6% with complete response (CR) rate of 24.6% and median DoR was 3.3 months (1-39). AITL patients were more sensitive than PTCL-NOS patients (ORR: 45.1 versus 20%, p = 0.01). Median PFS and OS were 3.1 (0.2-46.3) and 4.4 (0.2-55.4) months. On multivariate analysis, refractory disease (p = 0.001) and extranodal localization (p = 0.028) adversely influenced ORR. Grade 3-4 thrombocytopenia, neutropenia and infections were reported in 22, 17 and 23% of cases respectively.Bendamustine as single agent could be considered as a therapeutic option for relapsed or refractory PTCL, particularly in chemosensitive or AITL patients. Combinations of bendamustine with other drugs warrant further evaluation.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01475957
Contributor : Xavier Chard-Hutchinson <>
Submitted on : Friday, February 24, 2017 - 1:14:21 PM
Last modification on : Wednesday, August 19, 2020 - 1:26:05 PM

Links full text

Identifiers

Citation

Emilie Reboursiere, Fabien Le Bras, Charles Herbaux, Emmanuel Gyan, Aline Clavert, et al.. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.. Oncotarget, Impact journals, 2016, 7 (51), pp.85573-85583. ⟨10.18632/oncotarget.10764⟩. ⟨hal-01475957⟩

Share

Metrics

Record views

1360